Heart Scan to Check Coronary Artery Disease in People With Chronic Kidney Disease
Studies a heart scan measuring blood flow in adults with chronic kidney disease.
Plain-language title generated from the registry record
Registry title: Coronary Artery Disease Screening in Patients With Chronic Kidney Disease
Key facts
- Where
- La Tronche, FranceSee the site
Where in France
- Chu Grenoble AlpesLa Tronche, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Grenoble
- Trial code
- NCT07585695
- Record updated
- 14 May 2026
- Original description
Patients with chronic kidney disease (CKD) have a markedly increased cardiovascular risk, with coronary artery disease being a leading cause of morbidity and mortality. Conventional cardiovascular risk scores and non-invasive diagnostic tests have limited accuracy in this population, partly due to atypical symptoms and frequent structural heart disease. Coronary flow reserve (CFR) is a key marker of coronary microvascular dysfunction and has strong prognostic value, but its assessment is usually limited to invasive techniques. Recent advances in cadmium-zinc-telluride single-photon emission computed tomography (CZT-SPECT) allow non-invasive measurement of CFR. The EVACKD study aims to evaluate the prognostic value of CFR assessed by CZT-SPECT in patients with CKD for predicting major adverse cardiovascular events over a 2-year follow-up.Read full original descriptionShow less
Screening for Coronary Artery Disease in Patients With Chronic Kidney Disease
Patients with chronic kidney disease (CKD) have a markedly increased cardiovascular risk, with coronary artery disease being a leading cause of morbidity and mortality. Conventional cardiovascular risk scores and non-invasive diagnostic tests have limited accuracy in this population, partly due to atypical symptoms and frequent structural heart disease. Coronary flow reserve (CFR) is a key marker of coronary microvascular dysfunction and has strong prognostic value, but its assessment is usually limited to invasive techniques. Recent advances in cadmium-zinc-telluride single-photon emission computed tomography (CZT-SPECT) allow non-invasive measurement of CFR. The EVACKD study aims to evaluate the prognostic value of CFR assessed by CZT-SPECT in patients with CKD for predicting major adverse cardiovascular events over a 2-year follow-up.
Inclusion: Male or female patients aged over 18 years; Affiliated with the French social security system; Patients at renal risk based on albuminuria (Alb) and glomerular filtration rate (GFR < 30 mL/min/1.73 m², or GFR < 45 mL/min/1.73 m² with albuminuria > 30 mg/g, or GFR < 60 mL/min/1.73 m² with albuminuria > 300 mg/g); Patients undergoing, independently of the research and according to the clinician's decision as part of standard care, CZT-SPECT myocardial perfusion imaging with coronary flow reserve measurement for cardiovascular risk assessment; Having expressed no objection to participation in this study.
Exclusion: Legally protected adult (Article L1121-8 of the French Public Health Code); Person deprived of liberty (Article L1121-8 of the French Public Health Code); Pregnant woman; Patient who has undergone a normal coronary exploration within the past year.